Pharminent · Daily Brief
October 9, 2026
Regulatory & Approvals
FDA expands Roche’s Tecentriq label in dMMR colon cancer
The FDA expanded the label for Roche’s Tecentriq to cover dMMR stage III colon cancer. Tecentriq is the first immunotherapy indicated specifically for dMMR colon cancer, which is often linked to a higher risk of progression after surgery.
Pharmaceutical Technology →$RHHBY
NICE recommends daratumumab quadruplet for untreated multiple myeloma
NICE published final draft guidance recommending daratumumab with bortezomib, lenalidomide and dexamethasone (D-VRd) for previously untreated adults with multiple myeloma who are eligible for an autologous stem cell transplant. Patients can receive D-VRd as induction and consolidation treatment around their transplant, followed by daratumumab plus lenalidomide maintenance.
PharmaFile →
EMA makes ACT EU clinical trial advice pilot permanent
The EMA said the Accelerating Clinical Trials in the EU (ACT EU) advice pilot, which helps sponsors prepare clinical trial applications, will become a permanent initiative from January 2027.
EMA →
Clinical Data
argenx stops Sjögren’s study for futility, advances celiac drug
argenx shares fell after a data monitoring board recommended stopping a Vyvgart study in Sjögren’s disease for futility. The company also reported that FB102, the CD122 inhibitor obtained through its $2.2 billion acquisition of Forte, is moving into phase 3 testing in celiac disease.
BioPharma Dive →
Lilly reports phase 3b biomarker data on Taltz plus Zepbound
Lilly presented new exploratory data at Fall Clinical 2026 from the TOGETHER-PsO phase 3b study in adults with psoriasis and obesity, showing broader biomarker changes with Taltz (ixekizumab) plus Zepbound (tirzepatide) versus Taltz alone as early as Week 12.
Eli Lilly →$LLY
Deals & Partnerships
Viatris to acquire Pacira in $1.7B pain drug deal
Viatris agreed to acquire Pacira for $1.7 billion, gaining two non-opioid pain treatments that booked nearly $700 million in 2025 and could soon lose patent protection. Viatris said it would use its “intellectual property expertise” to sustain sales.
BioPharma Dive →
Biohaven licenses IgG degrader portfolio to Ono for $100M
Biohaven entered an exclusive regional collaboration and licensing agreement worth up to $100 million with Ono Pharmaceutical for its MoDE pan-IgG degrader portfolio.
Pharmaceutical Technology →
Roche partners with China’s Defand Therapeutics on drug discovery
Roche is partnering with Chinese startup Defand Therapeutics to discover new medicines, in a deal that goes beyond licensing.
STAT →$RHHBY
Business & Finance
TRex Bio prices $117M IPO for Treg-activating immune drugs
TRex Bio priced a $117 million IPO to fund development of drugs that treat immunological conditions by activating Treg cells. Eli Lilly is the largest equity holder in the company.
BioPharma Dive →$LLY
Iambic Therapeutics sets IPO terms to raise up to $160M
AI-powered drug discovery company Iambic Therapeutics announced the terms of its Nasdaq IPO, seeking to raise up to $160 million at a valuation of more than $800 million.
Pharmaphorum →
Matchpoint raises $150M for covalent immunology drugs
Matchpoint closed a $150 million financing round for its immunology-focused covalent drugs, with KymaThera, Rouge, Sensible Bio and Arboretum also announcing fundraises.
Pharmaphorum →
Arboretum LifeSciences launches with $30M in financing
Diagnostics and drug development startup Arboretum LifeSciences launched with $30 million in financing. Executives said analyses of data from its genetic tests form the basis of partnerships with large pharmaceutical companies and lead to the formation of new biotech companies, all focused on common diseases.
MedCity News →
Ultragenyx sells rare pediatric disease priority review voucher
Ultragenyx has sold a rare pediatric disease priority review voucher.
PharmExec →$RARE
Bio-Techne opens GMP small molecule facility in Bristol, UK
Bio-Techne Corporation opened a new manufacturing facility in Bristol, UK, dedicated to GMP grade small molecules.
Pharmaceutical Technology →
Forwarded this? Get your copy free
Sign up free →
Pharminent — Competitive Intelligence Suite · Tickers link to Yahoo Finance for reference only. Editorial framings are analysis, not investment advice. © 2026.